Literature DB >> 2145783

Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia.

D L Dresner1, S J Basta, H H Ali, A F Schwartz, P B Embree, W A Wargin, A A Lai, K A Brady, J J Savarese.   

Abstract

Preliminary disposition studies of the investigational, long-acting muscle relaxant doxacurium chloride (Nuromax) have demonstrated dual elimination by renal and hepatobiliary pathways, as well as slow hydrolysis by plasma cholinesterase. The present study compares the kinetics and dynamics of doxacurium in eight ASA physical status I or II elderly patients (67-72 yr of age) and eight ASA I or II young patients (22-49 yr of age). After institutionally approved written informed consent, kinetic and dynamic measurements were made after a 25-micrograms/kg bolus injection of doxacurium during 1.25 MAC nitrous oxide/oxygen/isoflurane anesthesia. Maximum twitch depression was similar in older patients (96.4% +/- 1.3%) to that in the young patients (96.6% +/- 1.8%). The time to achieve this level of block was significantly longer in the elderly than in the young (11.2 +/- 1.1 min versus 7.7 +/- 1.0 min, respectively). Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively). Elimination half-life (96 +/- 20 min) and clearance (2.47 +/- 0.69 mL.kg-1.min-1) in the elderly patients were not statistically different from values found in the younger group. Volume of distribution at steady state in the elderly (220 +/- 80.2 mL/kg) was significantly larger than in the young (150 +/- 40.0 mL/kg).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145783     DOI: 10.1213/00000539-199011000-00008

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  16 in total

1.  Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life.

Authors:  J Laurin; F Donati; F Nekka; F Varin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 3.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

5.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 6.  Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.

Authors:  D Faulds; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

7.  Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate.

Authors:  Y Zhu; G Audibert; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

Review 8.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 9.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.